Wells Fargo
ONCT

Wells Fargo’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Wells Fargo’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-408
Closed -$539 – 7314
2024
Q3 		$539 Buy
408
+108
+36% +$522 ﹤0.01% 6164
2024
Q2 		$2.28K Sell
300
-22
-7% -$189 ﹤0.01% 5993
2024
Q1 		$2.9K Buy
322
+1
+0.3% +$9 ﹤0.01% 5975
2023
Q4 		$3.44K Buy
321
+1
+0.3% +$7 ﹤0.01% 6014
2023
Q3 		$1.92K Buy
320
+1
+0.3% +$7 ﹤0.01% 6100
2023
Q2 		$2.2K Buy
319
+1
+0.3% +$7 ﹤0.01% 6194
2023
Q1 		$4.99K Buy
318
+1
+0.3% +$20 ﹤0.01% 6055
2022
Q4 		$6.34K Buy
317
+1
+0.3% +$20 ﹤0.01% 5704
2022
Q3 		$5K Buy
316
+1
+0.3% +$21 ﹤0.01% 5938
2022
Q2 		$7K Sell
315
-3,694
-92% -$82.4K ﹤0.01% 5921
2022
Q1 		$111K Sell
4,009
-3,619
-47% -$132K ﹤0.01% 5277
2021
Q4 		$347K Sell
7,628
-8,252
-52% -$555K ﹤0.01% 4950
2021
Q3 		$1.32M Buy
15,880
+10,946
+222% +$905K ﹤0.01% 4006
2021
Q2 		$469K Buy
4,934
+4,620
+1,471% +$548K ﹤0.01% 4656
2021
Q1 		$52K Buy
314
+56
+22% +$7.41K ﹤0.01% 5799
2020
Q4 		$26K Buy
258
+255
+8,500% +$16.1K ﹤0.01% 5798
2020
Q3 		$0 Hold
3
– – ﹤0.01% 7099
2020
Q2 		$0 Hold
3
– – ﹤0.01% 7003
2020
Q1 		$0 Buy
+3
New +$224 ﹤0.01% 7004
2019
Q3 		– Sell
-2
Closed – – 6821
2019
Q2 		$0 Sell
2
-4
-67% -$618 ﹤0.01% 6694
2019
Q1 		$1K Hold
6
– – ﹤0.01% 5980
2018
Q4 		$1K Sell
6
-57
-90% -$11.4K ﹤0.01% 6328
2018
Q3 		$14K Sell
63
-1
-2% -$2.4K ﹤0.01% 5917
2018
Q2 		$138K Buy
+64
New +$162K ﹤0.01% 5216
2018
Q1 		– Sell
-3
Closed -$4K – 6631
2017
Q4 		$4K Hold
3
– – ﹤0.01% 6101
2017
Q3 		$3K Hold
3
– – ﹤0.01% 6123
2017
Q2 		$2K Hold
3
– – ﹤0.01% 6064
2017
Q1 		$2K Sell
3
-4
-57% -$2.93K ﹤0.01% 6183
2016
Q4 		$5K Buy
7
+4
+133% +$4.28K ﹤0.01% 5964
2016
Q3 		$3K Hold
3
– – ﹤0.01% 6012
2016
Q2 		$2K Sell
3
-4
-57% -$3.74K ﹤0.01% 5963
2016
Q1 		$5K Hold
7
– – ﹤0.01% 5875
2015
Q4 		$7K Hold
7
– – ﹤0.01% 5819
2015
Q3 		$8K Buy
7
+4
+133% +$5.85K ﹤0.01% 5761
2015
Q2 		$5K Hold
3
– – ﹤0.01% 6029
2015
Q1 		$2K Hold
3
– – ﹤0.01% 5989
2014
Q4 		$3K Hold
3
– – ﹤0.01% 5967
2014
Q3 		$3K Hold
3
– – ﹤0.01% 5949
2014
Q2 		$5K Hold
3
– – ﹤0.01% 5808
2014
Q1 		$5K Sell
3
-9
-75% -$22.4K ﹤0.01% 5553
2013
Q4 		$27K Hold
12
– – ﹤0.01% 4930
2013
Q3 		$33K Buy
+12
New +$59.7K ﹤0.01% 4794

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Wells Fargo's ONCT Position: Q4 2024 in Review

Wells Fargo sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 408 shares — an estimated $539 sold.

Wells Fargo first reported a position in ONCT in Q3 2013 and held it in 42 quarters. The position peaked at $1.32M in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Wells Fargo reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Wells Fargo sold 408 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $539.
  • Wells Fargo first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 42 quarters.
  • Wells Fargo's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.32M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.